UCSF Study Shows Drug Reduces Risk Of Spine And Hip Fractures By Half In Women With Osteoporosis

December 22, 1998

A drug for the treatment of osteoporosis dramatically reduced the risk of spine and hip fractures by almost half and the risk of other painful fractures by 30 percent among women with osteoporosis, according to a study by University of California San Francisco researchers.

The drug, called alendronate, is a bisphosphonate that binds to bones and protects against bone loss. During a four-year study of 4432 postmenopausal women, 2214 participants received alendronate. New results from the study, part of the landmark Fracture Intervention Trial (FIT), are published in the December 23 issue of the Journal of American Medical Association (JAMA).

"Our study demonstrates that women who are concerned about osteoporosis or are over 60 or 65 years of age should have a bone density test so that they can be proactive about bone fracture prevention," said Steven R. Cummings, MD, UCSF professor of medicine and epidemiology and lead author of the study. "Women who do test positive for osteoporosis are at a very high risk of suffering a fracture, and should talk with their doctors about alendronate or other therapy for osteoporosis."

FIT, which included 6,000 patients, had two arms: the Vertebral Fracture Arm, which was previously reported at the 1997 American Society for Bone and Mineral Research Meeting and that included women who had a spinal fracture, and the Clinical Fracture Arm, which is the subject of this current study being reported in JAMA and that included women without spinal fractures.

Because 10 to 15 percent of postmenopausal women have spinal fractures, UCSF researchers aimed to determine in this Clinical Fracture Arm of the study whether four years of treatment with alendronate would reduce the risk of fractures in the large number of postmenopausal women who have a low bone mineral density (BMD), and therefore thin bones, but no spinal fractures. Cummings reported that the effect of alendronate on fractures depended on a woman's initial hip bone density measured at the beginning of the study, an indicator of whether or not she had osteoporosis. Those with the lowest BMD--and therefore the thinnest, most fragile bones, who are at the highest risk of fractures--benefited the most from alendronate. Women with osteoporosis were defined as those having a hip BMD 2.5 standard deviations below the normal mean.

The women in the study with a low enough BMD to qualify as osteoporotic experienced dramatic benefits from alendronate. However, those who did not have a low enough BMD to be classified as having osteoporosis, did not experience a reduction in the risk of fractures from taking the drug. All the women who received the drug during the four-year study did have a significant increase in BMD at the hip and spine, Cummings said.

During the four-year study, a total of 4432 women were randomized: 2214 to alendronate and 2218 to placebo (an inactive pill with no medical benefits). Participants were postmenopausal, between 54 to 81 years old (mean age 68 years), 97 percent Caucasian, and had a low neck BMD, but no spinal fractures. Women in the alendronate group were randomly assigned to 5 mg of the drug daily for the first two years followed by 10 mg daily for the remainder of the study.

Key findings of the FIT study include: "Although women in the study without osteoporosis did not experience a reduction in the risk of fractures from alendronate, our study will continue for another five years to assess the long-term effects of taking the drugs," Cummings said. He added that approximately one in five women who have osteoporosis--a disease that affects millions of women worldwide--don't know it. This is particularly dangerous because the bone weakening condition, if not treated appropriately, can lead to painful fractures that may greatly impact a woman's health and quality of life.

In fact, osteoporosis results in 1.5 million fractures each year, over 400,000 hospital admissions, more than 44 million patient days in nursing homes, and $13.8 billion in health care expenditures among women and men in the U.S. FIT is a collaborative effort of the University of California San Francisco and 11 other academic centers.

The first arm of the study (Vertebral Fracture Arm) included 2,027 postmenopausal women between the ages of 55 and 82 who had osteoporosis and previous spine fractures, as detected by x-ray. Researchers found that alendronate reduced the risk of hip fractures by 51 percent, spine fractures by 47 percent, and all clinical fractures by 28 percent.

Alendronate, which is available as FOSAMAX in 72 countries including the United States, was developed by Merck & Co. Inc., USA, which operates in many countries as Merck Sharp & Dohme.

Other researchers include Dennis M. Black, PhD, Lisa Palermo, Susan M. Rubin, MPH, University of California San Francisco Department of Epidemiology and Biostatistics; A. John Yates, MD, Desmond E. Thompson, PhD, Thomas A. Musliner, MD, Merck Research Labs, Rathway, New Jersey; William B. Applegate, MD, Department of Preventive Medicine, University of Tennessee; Elizabeth Barrett-Connor, MD, University of California San Diego; Andrea Z. La Croix, MD, Center for Health Studies, Group Health Cooperative, Seattle, Washington; Ronald Prineas, MD, University of Miami, Florida; Jean C. Scott, DrPH, University of Maryland, Baltimore; Thomas Vogt, MD, MPH, Cancer Research Center of Hawaii, Honolulu; Robert Wallace, MD, University of Iowa, Iowa City, Iowa.
-end-


University of California - San Francisco

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.